Objective: To assess the difference in exhaled nitric oxide levels in atopic and nonatopic asthmatic patients treated with anti-inflammatory drugs, and to compare exhaled nitric oxide measurement with lung function tests.
Introduction
Chronic airway inflammation plays a key role in asthma, but no marker has been routinely used for this condition in pediatric practice. Nitric oxide (NO) is a marker of this inflammation. Exhaled nitric oxide level is a useful indicator, and can be determined instantly (on-line) through sensitive, practical, easy, and noninvasive methods, which provide immediate, reliable, and standardized results. 1, 2 Measurement of exhaled nitric oxide can be used for the diagnosis and monitoring of responses to anti-inflammatory therapy, since untreated patients show high levels of exhaled nitric oxide. Due to the wide clinical and functional variability of this disorder, treatment schemes often have to be adjusted. [3] [4] [5] [6] [7] Exhaled nitric oxide can help with the detection of subclinical disorders, of insufficient anti-inflammatory therapy, and of treatment compliance, in addition to allowing the identification of patients at risk for asthma exacerbation. 8 Inhaled or systemic corticosteroids reduce exhaled nitric oxide levels. 9, 10 Thus, exhaled nitric oxide measurement can be used to monitor and quantify inflammation and it is therefore useful for individual control, and especially, for the management of inhaled corticosteroid doses.
The aim of the present study is to determine the clinical and functional profile and exhaled nitric oxide levels in atopic and nonatopic children and adolescents with persistent asthma. positive skin test results.
Exhaled nitric oxide measurement
Exhaled nitric oxide was measured on-line, using Endono ® (Seres, Aix-en-Provence, France), with the child in a comfortably sitting position, without physical activity prior to examination and without the use of any medication on the day of examination. Exhaled nitric oxide is measured by chemiluminescence, which counts the photons emitted at the return of NO molecules produced by NO reaction in the presence of excess ozone (O 3 ) to a more stable state; the light signal is proportional to the NO concentration.
NO was measured during a prolonged expiration of at least six seconds, in order to reach a plateau of at least three seconds, at a flow of 50 ml/s. 12 A plateau of two seconds in children younger than 12 years reduces the reliability of the exam. 13 The available devices for this exam detect NO of bronchopulmonary origin in the minimum values of a part per billion (ppb). 14 The cutoff point for the upper limit of normal corresponded to 10 ppb, according to the specificity of Endono ® and according to Franklin, 15 and was also the reference value adopted by the Division where the study was carried out.
Exhaled nitric oxide levels vary with devices and manufacturers, usually ranging between 10 and 20 ppb.
However, in healthy children and adolescents, levels around 10 ppb, ranging from 7.2 ppb (6.4-8.0 ppb) 15 to 8.7 ppb (8.1-9.2 ppb) have been described in the literature. 16 These levels are elevated in asthmatic patients, with rates 1.6 to 4.4 times greater than those found in healthy individuals. 17 During treatment with inhaled or systemic corticosteroids, these levels decrease or even return to normal.
Statistical analysis
Frequency distribution and means were calculated, and the chi-square test, Fishers exact test, and Students t test were used.
Results
Of 45 children and adolescents, 24 (53.3%) were atopic and 21 (46.6%), nonatopic. The characteristics of the study population are shown next (Table 1 ).
There was a male predominance (62.5%), and the age range was 6-13 years in 85% of the patients. The classification of asthma severity was similar in both groups (p = 1.0), but the group of atopic patients 
Discussion
The average exhaled nitric oxide levels (5.3 ppb) observed among nonatopic patients after treatment with inhaled corticosteroids, antileukotrienes and antihistamines are consistent with the reference values. [15] [16] [17] There was no agreement as to whether the presence of symptoms was higher in the atopic patient. In the present study, no statistically significant difference was observed between the groups; however, some authors have described such significance. 18, 19 The present study revealed that, even though asthma The authors concluded that the control group received a higher dose of inhaled corticosteroids than necessary and suggested that exhaled nitric oxide is a logical alternative to the adjustment of inhaled corticosteroid therapy.
Pijnenburg et al. 25 found that some atopic patients continue to have high levels of exhaled nitric oxide even after the prolonged use of inhaled corticosteroids, and that these levels remain high with the correct use of the inhalation technique and after an increase in the dose of inhaled corticosteroids.
Finally, the present study showed that exhaled nitric oxide measurement was better than spirometry, and the presence of symptoms for assessment of atopic asthmatic patients and the results obtained suggest that these patients are seemingly more susceptible to relapses than nonatopic individuals. 
